Loading provider…
Loading provider…
Hematology & Oncology Physician in Tampa, FL
NPI: 1225225865Primary Employer
Moffitt Medical Group
moffitt.org
HQ Phone
Get M.D. Asmita's Phone Numberphone_androidMobile
Get M.D. Asmita's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardFL State Medical License
FL State Medical License
2013 - 2027

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Hematology
University Of Louisville School Of Medicine
louisville.edu
Residency • Internal Medicine
2007 - 2010
University of South Florida Morsani College of Medicine/Moffitt Cancer Center/Tampa General Hospital
Fellowship • Hematology and Medical Oncology
2010 - 2013
St. George's University School of Medicine
Medical School
Until 2007
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 26 | 34 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 24 | 38 |
Transplant options and outcomes for TP53 myeloid disease.
Authors: Fernández, Hugo F, Mishra, Asmita
Journal: Hematology Am Soc Hematol Educ Program
Authors: Mishra, A, Bhat, A, Kumari, S, Sharma, R, Braynen, J, Tadesse, D, El Alaoui, S, Seaver, S, Grosjean, N, Ware, D, Xie, M, Paape, T
Journal: Plant Biol (Stuttg)
Publication Date: 2025-05-22
Authors: Maria Corrales-Yepez, Jeffrey Lancet, Javier Pinilla-Ibarz, Rami Komrokji, Eric Padron, Mohamed Kharfan Dabaja
Journal: Am J Hematol
Publication Date: 2013-05-30
Lead Sponsor: Aprea Therapeutics
Intervention / Treatment: DRUG: APR-246
Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Intervention / Treatment: BIOLOGICAL: Cultured Treg cells
Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Intervention / Treatment: DRUG: Ofatumumab